A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Federal, Argentina
-
-
-
-
-
Bedford, Australia
-
Box Hill, Australia
-
Garran, Australia
-
Herston, Australia
-
Kogarah, Australia
-
Parkville, Australia
-
Perth, Australia
-
South Brisbane, Australia
-
-
-
-
-
Innsbruck, Austria
-
Wien, Austria
-
-
-
-
-
Antwerpen, Belgium
-
Brussel, Belgium
-
Imeldalaan 9, Belgium
-
Leuven, Belgium
-
-
-
-
-
Edmonton, Canada
-
Halifax, Canada
-
Quebec, Canada
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
Vancouver N/A, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal N/A, Quebec, Canada
-
-
-
-
-
Pardubice, Czechia
-
Praha 10, Czechia
-
-
-
-
-
Aalborg, Denmark
-
Aarhus C., Denmark
-
Hvidovre N/A, Denmark
-
København, Denmark
-
-
-
-
-
Lille, France
-
Nancy Cedex, France
-
Paris, France
-
Strasbourg Cedex, France
-
Toulouse, France
-
-
-
-
-
Berlin N/A, Germany
-
München, Germany
-
Stade, Germany
-
-
-
-
-
Jerusalem, Israel
-
Kfar Saba, Israel
-
Rehovot, Israel
-
Tel-Aviv, Israel
-
-
-
-
-
Eindhoven, Netherlands
-
Nijmegen, Netherlands
-
Rotterdam, Netherlands
-
-
-
-
-
Auckland, New Zealand
-
Christchurch, New Zealand
-
-
-
-
-
Basel, Switzerland
-
Bern, Switzerland
-
Zurich, Switzerland
-
-
-
-
-
Cardiff, United Kingdom
-
Dundee, United Kingdom
-
Glasgow, United Kingdom
-
Harrow, United Kingdom
-
Liverpool, United Kingdom
-
London, United Kingdom
-
Manchester, United Kingdom
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States
-
-
California
-
Anaheim, California, United States
-
Los Angeles, California, United States
-
Oakland, California, United States
-
Orange, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Hartford, Connecticut, United States
-
-
Florida
-
Orlando, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Louisiana
-
Metairie, Louisiana, United States
-
-
Maryland
-
Laurel, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Minnesota
-
Plymouth, Minnesota, United States
-
Rochester, Minnesota, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nebraska
-
Lincoln, Nebraska, United States
-
-
New Jersey
-
Egg Harbor Township, New Jersey, United States
-
-
New York
-
Great Neck, New York, United States
-
New Hyde Park, New York, United States
-
New York, New York, United States
-
Rochester, New York, United States
-
-
North Carolina
-
Asheville, North Carolina, United States
-
Chapel Hill, North Carolina, United States
-
Charlotte, North Carolina, United States
-
Durham, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Cleveland, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
Tulsa, Oklahoma, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Beaver Falls, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
Rhode Island
-
Providence, Rhode Island, United States
-
-
Tennessee
-
Memphis, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Vermont
-
Burlington, Vermont, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients enrolled in three Phase 3 Janssen-sponsored (C0168T37, C0168T46, C0168T72) infliximab clinical studies in ulcerative colitis that require long-term safety follow-up
- Patients must have received at least 1 dose of study agent to be eligible for participation in the study
Exclusion Criteria:
- Patients who refuse consent or are unwilling to respond to requests for long-term safety information within the required timeframe will be excluded. In addition, patients participating in a study extension to the primary study are not eligible for participation in the C0168T62 study during the study extension participation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Infliximab 5 mg/kg
This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
|
Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
|
|
Infliximab 10 mg/kg
This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
|
Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
|
|
Placebo
This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
|
Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with adverse events as a measure of safety
Time Frame: 5 years
|
Long-term safety will be evaluated by assessment of serious infections,new malignancies (including colorectal cancer), new autoimmune diseases, death, delayed hypersensitivity (serum sickness-like) reactions, or dysplasia of the colon and other non-serious adverse events.
Non-serious adverse events will be collected for participants continuing at the beginning of collection of non-serious adverse events.
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with malignancies by malignancy type
Time Frame: 5 years
|
Number of patients with malignancies by malignancy type (ie, lymphoma, nonmelanoma skin cancers, other malignancies)
|
5 years
|
|
Number of patients with serious infections by type of infection
Time Frame: 5 years
|
5 years
|
|
|
Number of patients with surgical procedures (including colectomy) for the treatment of ulcerative colitis
Time Frame: 5 years
|
5 years
|
|
|
Number of patients with hospitalizations for the treatment of ulcerative colitis
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR004801
- C0168T62 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.